PDCD1 and hepatocellular carcinoma: To observe the efficacy of VS4718, anti-PD1 monotherapy or the combination of VS4718 and anti-PD1 in the treatment of HCC, we established a C57BL/6 J primary HCC model with complete immune function and then randomly grouped them for drug administration (Figure 2A).